ENTEREG Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Entereg patents expire, and what generic alternatives are available?
Entereg is a drug marketed by Cubist Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has one patent family member in one country.
The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alvimopan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Entereg
A generic version of ENTEREG was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.
Summary for ENTEREG
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Clinical Trials: | 16 |
| Patent Applications: | 33 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ENTEREG |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENTEREG |
| What excipients (inactive ingredients) are in ENTEREG? | ENTEREG excipients list |
| DailyMed Link: | ENTEREG at DailyMed |
Recent Clinical Trials for ENTEREG
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Scott Steele | Phase 4 |
| The Cleveland Clinic | Phase 4 |
| Brigham and Women's Hospital | Phase 3 |
Pharmacology for ENTEREG
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ENTEREG
US Patents and Regulatory Information for ENTEREG
ENTEREG is protected by one US patents.
Patents protecting ENTEREG
Methods of preventing and treating gastrointestinal dysfunction
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENTEREG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ENTEREG
See the table below for patents covering ENTEREG around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Greece | 3036136 | ⤷ Try a Trial | |
| Slovenia | 657428 | ⤷ Try a Trial | |
| Czech Republic | 290559 | Krystalické 4-fenylpiperidinové sloučeniny ve formě dihydrátu, způsob jejich přípravy, meziprodukty a farmaceutický prostředek s jejich obsahem (Crystalline 4-phenylpiperidine compounds in the form of dihydrate, process of their preparation, intermediates and pharmaceutical preparation containing thereof) | ⤷ Try a Trial |
| Yugoslavia | 70294 | ⤷ Try a Trial | |
| South Africa | 9202180 | ⤷ Try a Trial | |
| Ireland | 921003 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
